PAI Partners to acquire SGD Pharma from China Jianyin Investment for c.$1bn.

PAI Partners, a private equity firm, agreed to acquire SGD Pharma, a provider of production and decoration of glass bottles, from China Jianyin Investment, a Chinese investment company, for c.$1bn. "By investing in cutting-edge manufacturing technologies, in taking the lead on sustainability and through constantly improving the service level it offers to its clients, the SGD Pharma teams have built a solid platform for performance and growth under JIC’s ownership. We are now thrilled to contemplate the next stage of SGD Pharma’s development with PAI – an experienced and supportive partner," Christophe Nicoli, SGD Pharma CEO.